AQR Capital Management
MRTX

AQR Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

AQR Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,292
Closed -$1.99M – 2356
2021
Q2 		$1.99M Sell
12,292
-4,933
-29% -$792K ﹤0.01% 1221
2021
Q1 		$2.95M Sell
17,225
-3,270
-16% -$647K ﹤0.01% 998
2020
Q4 		$4.5M Buy
20,495
+7,745
+61% +$1.67M 0.01% 811
2020
Q3 		$2.12M Sell
12,750
-3,463
-21% -$474K ﹤0.01% 1082
2020
Q2 		$1.85M Buy
16,213
+993
+7% +$96.3K ﹤0.01% 1189
2020
Q1 		$1.17M Buy
15,220
+1,556
+11% +$140K ﹤0.01% 1272
2019
Q4 		$1.76M Buy
13,664
+1,725
+14% +$166K ﹤0.01% 1319
2019
Q3 		$930K Sell
11,939
-673
-5% -$63.2K ﹤0.01% 1542
2019
Q2 		$1.3M Sell
12,612
-3,263
-21% -$254K ﹤0.01% 1407
2019
Q1 		$1.16M Sell
15,875
-58,336
-79% -$3.97M ﹤0.01% 1508
2018
Q4 		$3.15M Sell
74,211
-13,209
-15% -$526K ﹤0.01% 1091
2018
Q3 		$4.12M Buy
87,420
+34,501
+65% +$1.92M ﹤0.01% 1082
2018
Q2 		$2.61M Buy
+52,919
New +$2M ﹤0.01% 1305
2017
Q3 		– Sell
-26,464
Closed -$97K – 2300
2017
Q2 		$97K Hold
26,464
– – ﹤0.01% 2177
2017
Q1 		$138K Sell
26,464
-30,873
-54% -$169K ﹤0.01% 2149
2016
Q4 		$272K Sell
57,337
-13,195
-19% -$71.8K ﹤0.01% 2081
2016
Q3 		$466K Buy
+70,532
New +$375K ﹤0.01% 1964
2016
Q2 		– Sell
-11,525
Closed -$247K – 2276
2016
Q1 		$247K Sell
11,525
-1,367
-11% -$30.6K ﹤0.01% 2061
2015
Q4 		$408K Sell
12,892
-389
-3% -$13.7K ﹤0.01% 1944
2015
Q3 		$457K Buy
13,281
+830
+7% +$25.1K ﹤0.01% 1756
2015
Q2 		$392K Buy
+12,451
New +$367K ﹤0.01% 1880

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

AQR Capital Management's MRTX Position: Q3 2021 in Review

AQR Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2021, closing a stake of 12,292 shares — an estimated $1.99M sold.

AQR Capital Management first reported a position in MRTX in Q2 2015 and held it in 21 quarters. The position peaked at $4.5M in Q4 2020. 238 funds tracked by Wall St. Rank hold MRTX as of Q3 2021.

  • AQR Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • AQR Capital Management sold 12,292 Mirati Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $1.99M.
  • AQR Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2015 and held it in 21 quarters.
  • AQR Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $4.5M in Q4 2020.
  • 238 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2021.

Based on AQR Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.